Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
November 02, 2021
Marche-en-Famenne, Belgium
About
Bioxodes
Bioxodes takes advantage of its deep understanding of the thrombotic process to design drug candidates with an aim to achieve anticoagulation without hemorrhagic risk.
Our lead drug candidate, Ir-CPI, targets coagulation factors XIIa and XIa and prevents Neutrophil Extracellular Trap (NET) release, key driver components of the thrombo-inflammatory process.
In parallel, Bioxodes is developing a pipeline of drug candidates targeting chronic inflammatory diseases.
Our innovative pipeline includes a clinical-stage program with Ir-CPI for the prevention of acute thrombo-inflammatory processes. The initiation of the Phase IIa program to collect first evidence of efficacy in patients is expected early 2022.
Product
All products-
![]()
Ir-CPI
With its unique mechanism of action on neutrophils and coagulation factors (FXIa and FXIIa), Ir-CPI displays an antithrombotic activity.
Read more -
![]()
Pipeline
Bioxodes is building an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.
Read More -
![]()
Clinical trials
Clinical trials are being conducted to assess the safety and efficacy of Ir-CPI in thrombo-inflammatory diseases.
Read More
Scientific & Clinical Advisory Board
All Key opinion leaders-
Read more
Thomas Lecompte , M.D
Geneva, Switzerland
-
Read more
Jeff Weitz , M.D
Ontario, Canada
-
Read more
François Pattou , M.D
Lille, France
-
Read more
Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)
Brussels, Belgium
-
Read more
Christophe Dubois , Ph.D
Marseille, France
-
Read more
Denis Vivien , Ph.D
Caen, France
-
Read more
Thomas Marichal , Ph.D
Liège, Belgium
Recents News
Investors
Invest in us
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
